899 related articles for article (PubMed ID: 30419129)
1. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
2. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
3. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
[TBL] [Abstract][Full Text] [Related]
4. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
5. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
6. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
7. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
8. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
[TBL] [Abstract][Full Text] [Related]
9. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
Figge JJ; Gooding WE; Steward DL; Yip L; Sippel RS; Yang SP; Scheri RP; Sipos JA; Mandel SJ; Mayson SE; Burman KD; Folek JM; Haugen BR; Sosa JA; Parameswaran R; Tan WB; Nikiforov YE; Carty SE
Thyroid; 2021 Nov; 31(11):1673-1682. PubMed ID: 34340592
[No Abstract] [Full Text] [Related]
10. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
11. Multiplatform molecular test performance in indeterminate thyroid nodules.
Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
[TBL] [Abstract][Full Text] [Related]
12. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
13. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
[No Abstract] [Full Text] [Related]
14. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
15. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
16. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
17. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
18. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
19. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
[TBL] [Abstract][Full Text] [Related]
20. A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials.
Zafereo M; McIver B; Vargas-Salas S; Domínguez JM; Steward DL; Holsinger FC; Kandil E; Williams M; Cruz F; Loyola S; Solar A; Roa JC; León A; Droppelman N; Lobos M; Arias T; Kong CS; Busaidy N; Grubbs EG; Graham P; Stewart J; Tang A; Wang J; Orloff L; Henríquez M; Lagos M; Osorio M; Schachter D; Franco C; Medina F; Wohllk N; Diaz RE; Veliz J; Horvath E; Tala H; Pineda P; Arroyo P; Vasquez F; Traipe E; Marín L; Miranda G; Bruce E; Bracamonte M; Mena N; González HE
Thyroid; 2020 May; 30(5):704-712. PubMed ID: 31910118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
